IQVIA Holdings Inc.
IQVIA Holdings Inc. is classed by the SEC under Services-Commercial Physical & Biological Research (industry code 8731), based in Durham, NC. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $16 billion and a profit of $1.4 billion (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a project business: prior from its industry code (SEC 8731, Services-Commercial Physical & Biological Research); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.6 out of ten, 9 of 9 metrics filed: past 7.3 out of ten, present 7.0 out of ten, future 5.2 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 7.9 out of ten. No warning events in its filings since 2017. 79th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 8.0 out of ten. +10.2% a year over 10 filed years; profitable in 10 of 10. 80th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 4.8 out of ten. Share count shrank 3.1% a year. 48% of cash flow returned. Insiders: 17 sales, 0 purchases. 48th percentile among 6 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 5.6 out of ten. ROE 21%: 21¢ of profit per shareholder dollar. Leverage 78%: owes 78¢ per asset dollar. 56th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 7.6 out of ten. top 24% of 12 in its family; net margin 8.3%. 76th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 7.6 out of ten. top 24% of 8 in its family for leadership; chief executive since 2016. 76th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 4.2 out of ten. bottom 42% of 12 in its family for room to expand. 42nd percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 4.8 out of ten. bottom 48% of 12 in its family for growth drivers. 48th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 6.5 out of ten. top 35% of 11 in its family for expectations against reality. 65th percentile among 11 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-17 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-07-28 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-07-28 (on EDGAR). Newest filing: Form 8-K, 2026-09-23. Filings on record since 2009. Read from EDGAR 2026-10-12.
Where the revenue comes from
Lines of business in fiscal 2025: Research and Development Solutions 55%, Technology and Analytics Solutions 41%, Contract Sales and Medical Solutions 5%. By geography: Americas 48%, Europe and Africa 32%, Asia-Pacific 21%. As tagged in its annual report (Form 10-K, filed 2026-02-17).
Who runs it
Bousbib, Ari (Chairman, Chief Executive Officer & President Power of Attorney); Patel, Bhavik (President, MedTech and Consumer Health Power of Attorney); Staub, W Richard (President, Research & Development Solutions Power of Attorney); Sherbet, Eric (Executive Vice President, General Counsel Power of Attorney); Grenfell, Alistair (President, Commercial Solutions); Bruehlman, Ronald E (EVP & Chief Financial Officer); Berkshire, James G. (EVP, Global Infrastructure and Operations. Power of Attorney); Cherofsky, Keriann (SVP, Corporate Controller Power of Attorney); Fedock, Michael J. (SVP, FP&A); Haas, Bernd (EVP, AI and Technology Solutions.); and 8 more. 18 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.